Brand-name pharmaceutical companies have become skilled at extending their market dominance well beyond the exclusivity period Congress intended, using patent strategies and litigation tactics that block lower-cost generic and biosimilar drugs from reaching patients, according to a new series from the R Street Institute. The analysis examines how patent thickets, product hopping, and repeated lawsuits create barriers to competition that threaten access to affordable prescription drugs. Despite laws designed to encourage both innovation and competition, drugmakers have learned to exploit the system through weak patents and legal maneuvers that keep generics off pharmacy shelves.
The United States leads the world in pharmaceutical research and development, spending $103 billion in 2024, the report notes. Congress created pathways for generic competition through the Hatch-Waxman Act in 1984 and the Biologics Price Competition and Innovation Act in 2009, both aimed at balancing continued innovation with market competition. Generic drugs now account for 90 percent of all prescriptions filled in the United States, delivering billions of dollars in savings to patients, consumers, and taxpayers annually. Yet brand-name companies have grown adept at building what the report calls patent thickets—clusters of low-quality patents with only minor variations from earlier patents—that are strategically used to delay competition and fuel litigation against would-be competitors.
The report finds that the interplay between the patent system and the Food and Drug Administration's drug approval process has created opportunities for strategic exploitation that undermine the original intent of federal law. The series examines how terminal disclaimers, originally a judicial tool to prevent patent term extension, have evolved into a mechanism for constructing patent thickets that postpone generic and biosimilar entry. According to the analysis, the Hatch-Waxman generic approval process can be manipulated to discourage generic entry through serial litigation, where the process itself becomes a penalty that deters competition regardless of patent merit.
The report's analysis suggests that patents play an essential role in pharmaceutical innovation by allowing inventors to recover costs from risky investments through limited exclusivity, with the tradeoff that inventions become public knowledge accessible to all. However, when companies deploy patent gamesmanship—filing multiple patents with trivial modifications and launching wave after wave of lawsuits—they extend monopoly power beyond what the law envisioned. This delays the moment when generics can enter the market and drive down prices through competition. The report explains that these tactics threaten the balance Congress tried to strike between rewarding genuine innovation and ensuring timely access to affordable alternatives.
The series points to bipartisan legislation now pending in the 119th Congress that would address patent thickets, product hopping, skinny labeling, and interagency coordination. Both chambers and both parties have introduced bills to counter anticompetitive practices and reform key patent rules in response to mounting concerns over drug affordability. The report examines the ETHIC Act, introduced in both the House and Senate, which would limit some of the delay tactics that keep lower-cost generic and biosimilar drugs out of reach. The takeaway is clear: without structural reforms to close loopholes in the patent and approval systems, patients will continue paying more for medicines than necessary while drugmakers profit from legal strategies rather than true innovation.